Maravai Lifesciences Financials

MRVI Stock  USD 2.30  0.06  2.68%   
Based on the key indicators related to Maravai Lifesciences' liquidity, profitability, solvency, and operating efficiency, Maravai Lifesciences Holdings is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. As of now, Maravai Lifesciences' Net Tangible Assets are increasing as compared to previous years. The Maravai Lifesciences' current Retained Earnings is estimated to increase to about 147.1 M, while Short and Long Term Debt Total is projected to decrease to under 35.5 M. Key indicators impacting Maravai Lifesciences' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.110.1148
Sufficiently Down
Slightly volatile
Current Ratio4.267.5327
Way Down
Slightly volatile
The financial analysis of Maravai Lifesciences is a critical element in measuring its lifeblood. Investors should not minimize Maravai Lifesciences' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(137.6 Million)

  

Maravai Lifesciences Holdings Earnings Geography

Maravai Lifesciences Stock Summary

Maravai Lifesciences competes with Roivant Sciences, Krystal Biotech, Akero Therapeutics, Apellis Pharmaceuticals, and Halozyme Therapeutics. Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California. Maravai LifeSciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 470 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS56600D1072
CUSIP56600D107
LocationCalifornia; U.S.A
Business Address10770 Wateridge Circle,
SectorLife Sciences Tools & Services
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.maravai.com
Phone858 546 0004
CurrencyUSD - US Dollar

Maravai Lifesciences Key Financial Ratios

Maravai Lifesciences Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets1.3B1.9B2.3B1.5B1.0B1.4B
Other Current Liab40.8M64.3M88.3M59.5M36.4M52.9M
Other Liab15.9M400.4M713.6M693.4M797.4M405.2M
Net Tangible Assets(280.7M)(313.4M)315.5M44.9M51.6M54.2M
Net Debt354.6M(17.0M)(46.9M)36.0M(285.1M)(270.8M)
Retained Earnings854K184.6M404.8M285.7M140.9M147.1M
Accounts Payable3.0M8.2M6.0M10.7M12.0M8.0M
Cash236.2M551.3M632.1M575.0M322.4M371.4M
Other Assets805K435.9M812.5M806.1M927.0M973.4M
Long Term Debt528.6M524.6M522.0M518.7M290.5M480.0M
Net Receivables51.0M117.5M146.8M55.7M38.5M69.7M
Inventory33.3M51.6M43.2M51.4M50.1M40.5M
Other Current Assets11.1M19.7M25.8M17.8M18.1M15.4M
Total Liab1.1B1.4B1.4B697.6M431.0M409.5M
Net Invested Capital623.1M846.1M1.1B940.9M621.2M795.9M
Total Current Assets331.6M740.0M847.9M699.9M429.1M497.0M
Capital Stock2.6M2.6M2.6M2.5M2.5M2.4M
Net Working Capital200.8M646.3M737.8M612.4M372.2M411.5M
Short Term Debt10.6M9.7M11.7M12.9M5.4M8.7M
Intangible Assets177.7M117.6M216.7M221.0M195.0M211.2M
Common Stock2.6M2.6M2.6M2.5M2.5M2.4M

Maravai Lifesciences Key Income Statement Accounts

202020212022202320242025 (projected)
Tax Provision2.9M61.5M60.8M(1.6M)(1.9M)(1.8M)
Net Interest Income(30.7M)(30.3M)(18.1M)(18.1M)(20.3M)(21.3M)
Interest Expense30.7M30.3M20.4M45.9M47.7M36.5M
Total Revenue284.1M799.2M883.0M288.9M259.2M437.1M
Gross Profit204.4M658.7M714.0M140.2M108.3M102.9M
Operating Income67.6M554.6M574.2M(31.6M)(235.6M)(223.8M)
Ebit112.4M561.0M571.9M663.6M(213.8M)(203.1M)
Research Development9.3M15.2M18.4M17.3M19.2M13.8M
Ebitda138.3M585.8M610.0M712.4M(156.9M)(149.1M)
Cost Of Revenue79.6M140.6M169.0M148.7M150.9M128.3M
Income Before Tax81.7M530.8M551.5M617.7M(261.5M)(248.4M)
Net Income76.9M469.3M490.7M(119.0M)(144.8M)(137.6M)
Income Tax Expense2.9M61.5M60.8M756.1M(1.9M)(1.8M)
Minority Interest66.2M(287.2M)(270.5M)(34.5M)114.8M120.5M

Maravai Lifesciences Key Cash Accounts

202020212022202320242025 (projected)
Change To Inventory(19.1M)(21.6M)9.5M649K377K395.9K
Investments6.1M105.7M(267.6M)(127.9M)(24.3M)(25.5M)
Change In Cash211.5M315.1M80.9M(57.2M)(252.6M)(239.9M)
Net Borrowings(2.6M)196.9M(6M)(5.4M)(4.9M)(4.7M)
Free Cash Flow126.8M353.7M518.9M60.7M(22.2M)(21.1M)
Depreciation25.8M24.8M38.1M48.8M48.4M36.5M
Other Non Cash Items(7.5M)(6.2M)(8.7M)(690.9M)169.3M177.7M
Capital Expenditures25.4M14.9M17.1M65.6M29.7M27.2M
Net Income78.8M469.3M490.7M(119.0M)(259.6M)(246.6M)
End Period Cash Flow236.2M551.3M632.1M575.0M322.4M371.4M
Change To Netincome477K(340K)45.8M320.0M368.0M386.4M

Maravai Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Maravai Lifesciences's current stock value. Our valuation model uses many indicators to compare Maravai Lifesciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Maravai Lifesciences competition to find correlations between indicators driving Maravai Lifesciences's intrinsic value. More Info.
Maravai Lifesciences Holdings is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Maravai Lifesciences' Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Maravai Lifesciences' earnings, one of the primary drivers of an investment's value.

Maravai Lifesciences' Earnings Breakdown by Geography

Maravai Lifesciences Systematic Risk

Maravai Lifesciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Maravai Lifesciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Maravai Lifesciences correlated with the market. If Beta is less than 0 Maravai Lifesciences generally moves in the opposite direction as compared to the market. If Maravai Lifesciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Maravai Lifesciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Maravai Lifesciences is generally in the same direction as the market. If Beta > 1 Maravai Lifesciences moves generally in the same direction as, but more than the movement of the benchmark.

Maravai Lifesciences Thematic Clasifications

Maravai Lifesciences Holdings is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Pharmaceutical ProductsView
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Maravai Lifesciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Maravai Lifesciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Maravai Lifesciences growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.3)

As of now, Maravai Lifesciences' Price Earnings To Growth Ratio is decreasing as compared to previous years.

Maravai Lifesciences March 26, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Maravai Lifesciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Maravai Lifesciences Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Maravai Lifesciences Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Maravai Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Maravai Lifesciences's daily price indicators and compare them against related drivers.

Complementary Tools for Maravai Stock analysis

When running Maravai Lifesciences' price analysis, check to measure Maravai Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maravai Lifesciences is operating at the current time. Most of Maravai Lifesciences' value examination focuses on studying past and present price action to predict the probability of Maravai Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maravai Lifesciences' price. Additionally, you may evaluate how the addition of Maravai Lifesciences to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Commodity Directory
Find actively traded commodities issued by global exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios